In the cross-sectional DIabetes REsearCh on patient straTification (DIRECT) study, we investigated basal and post-meal GLP-1 levels in diabetic patients
Repurposing GLP-1 receptor agonists and novel dual/triple GLP-1, GIP, and glucagon agonists represent promising therapeutic strategies that have shown to be effective in targeting inflammation, tau phosphorylation, synaptic dysfunction, insulin resistance, and oxidative stress
Industry analysts at PolicyLab put it plainly: evaluate providers on 12-month all-in cost at your maintenance dose, not the starter sticker
Clinical trials and real-world evidence treat obesity as a chronic condition, much like high blood pressure or diabetes, which means it usually requires ongoing treatment rather than a short-term fix
For research-supply positioning, this question should be reframed around experimental protocol design rather than use instructions
The theory is straightforward: slower absorption means a gentler onset of the medication effects, reducing the sharp spike that can trigger bloating and nausea in sensitive individuals
